A Phase Ib, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody(Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2015
At a glance
- Drugs Sevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Jiangsu Simcere Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 14 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 25 Sep 2015 Planned number of patients changed from 22 to 36 as per ClinicalTrials.gov record.